Your Messages Inbox
Your Article Summary
See Latest ArticlesBevacizumab: Monoclonal antibody approved for the treatment of metastatic renal cell carcinoma in combination with interferon alfa
Formulary , 09/17/09
Bevacizumab is a recombinant humanized monoclonal antibody (mAb) that inhibits the activity of human vascular endothelial growth factor, thereby inhibiting angiogenesis. This agent was approved on July, 2009, for use in combination with interferon alfa for the treatment of metastatic renal cell carcinoma.
Related Articles
Chromosomal abnormalities of clear cell renal cell carcinoma: Frequent gain of chromosome 7
Pathology International, 11/19/09
Relevance Score: 89%
Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma
British Journal of Cancer, 11/20/09
Relevance Score: 84%
Population-based survey of cancer risks in chromosome 3 translocation carriers
Genes, Chromosomes and Cancer, 10/28/09
Relevance Score: 84%
Apolipoprotein E/C1 Locus Variants Modify Renal Cell Carcinoma Risk
Cancer Research, 10/20/09
Relevance Score: 84%
Surgical Treatment of Renal Cell Carcinoma in the Immunocompromised Transplant Patient
Urology, 10/12/09
Relevance Score: 84%
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Sanofi Pasteur obtains license from Syntiron to develop & commercialize vaccine to prevent Staphylococcus infections
Sanofi-aventis, 12/17/09
Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09
Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09
Article Search
Sponsor